)
Mankind Pharma (MANKIND) investor relations material
Mankind Pharma Q3 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 FY26 consolidated revenue rose 11.5% year-on-year to ₹3,567 crore, with nine-month revenue at ₹10,835 crore, driven by domestic pharma, chronic therapies, and BSV consolidation.
Adjusted EBITDA margin was 25.9% for Q3, with net profit up 9.5% year-on-year to ₹414 crore; diluted EPS at ₹9.9.
Chronic segment share increased by 200 bps year-on-year, with strong growth in cardiac (+16.7%) and anti-diabetes (+14.4%) therapies.
Strategic transformation initiatives and BSV integration improved workforce stability, brand portfolio, and business recovery.
Unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, were approved, with unmodified auditor conclusions.
Financial highlights
Q3 FY26 consolidated revenue: ₹3,567 crore (up 11.5% YoY); nine-month revenue: ₹10,835 crore (up 18.7% YoY).
Adjusted EBITDA margin at 25.9% for Q3; gross margin improved to 72.6% (up 170 bps YoY).
Q3 FY26 PAT: ₹414 crore (up 9.5% YoY); nine-month PAT: ₹1,379 crore.
Export revenues increased 14% YoY in Q3 and 51% for nine months, reaching ₹1,503 crore.
Cash EPS increased 12.1% YoY to ₹15.6.
Outlook and guidance
Management expects continued recovery in acute segment and double-digit growth in OTC and chronic therapies.
Guidance for Q4 and next year to be provided in the next quarter; Q4 expected to show double-digit growth.
Management continues to monitor regulatory developments, especially labor codes, and will adjust accounting as needed.
- TimeTickerHeadlineOpen
- 5 FebMCFT
Q2 FY2026 sales up 13.2%, guidance raised, and $232M Marine Products deal to drive synergies. - 5 FebKLIC
Q1 2026 revenue up 20%, strong margins, robust Q2 outlook, and ongoing market risks. - 5 FebNSIT
Record Q4 profit and margin; 2026 guidance sees EPS growth and stable margins. - 5 FebITT
Record 2025 growth, strong cash flow, and positive 2026 outlook with SPX FLOW acquisition. - 5 FebROK
Double-digit sales and EPS growth drive raised 2026 guidance and strong segment performance. - 5 FebCLB
Q4 2025 revenue up 7% year-over-year; net debt and shares outstanding declined. - 5 FebBLSH
Record Q4 growth and options momentum set stage for strong 2026 expansion and tokenization. - 5 Feb2802
Record sales and profit highs, with raised full-year profit outlook and strong Q4 drivers. - 5 FebECB
Rates held steady as inflation nears 2% target; growth and reforms remain key priorities. - 5 FebBSET
Q4 2025 delivered revenue and profit growth, led by cost control and strong sales.
Next Mankind Pharma earnings date
Next Mankind Pharma earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)